14 Jun 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

CFO acquired shares in FluoGuide


January 25, 2023

FluoGuide A/S (“FluoGuide” or the “Company”) announce that the CFO of FluoGuide, Henrik Hang, has acquired 500 shares in the Company on 24 January 2023 at a value approx. 55,55 SEK per share on Nasdaq First North Growth Market, Stockholm.

“I have acquired new shares in FluoGuide due to the fact that FluoGuide have reached several important milestones and significant progress in clinical development during 2022. In addition, FluoGuide will announce the top-line results and data on the ongoing trials in 2023”, says Henrik Hang, CFO of FluoGuide.

For further information, please contact:

Morten Albrechtsen, CEO
FluoGuide A/S
+45 24 25 62 66

Certified Adviser: Svensk Kapitalmarknadsgransking AB

About FluoGuide

FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company has demonstrated efficacy of F001 as well as it being well tolerated and safe in the completed proof-of-concept clinical study (phase I/IIa) in patients with high grade glioma undergoing surgery. A phase IIb trial in aggressive brain cancer is ongoing to obtain valuable information to design the phase III trial. In addition, FluoGuide currently explores FG001 lung and head & neck cancer, and a trail in in meningioma and low grade glioma is commencing. FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker “FLUO”, please visit